Advertisement

Topics

Bayer In Agreement To Develop Therapies Targeting Genetic Cancer Drivers

06:29 EST 15 Nov 2017 | Pharmaceutical Processing

The company has entered into an exclusive global collaboration with a biopharmaceutical company for the development and commercialization of compounds, including larotrectinib, an investigational oral and selective TRK inhibitor.
Contributed Author: 
Bayer AG

Original Article: Bayer In Agreement To Develop Therapies Targeting Genetic Cancer Drivers

NEXT ARTICLE

More From BioPortfolio on "Bayer In Agreement To Develop Therapies Targeting Genetic Cancer Drivers"

Advertisement
Quick Search
Advertisement
Advertisement